Executive summary. Developing a medical cannabis medicine is not a matter of growing a consistent cultivar and choosing a brand name. The pathway integrates product classification, pharmaceutical development, non-clinical evidence, clinical evidence, scalable manufacture, analytical control, stability, regulatory submission and post-market oversight.
Target product profile
Development begins by defining the intended indication, patient population, route, dose, dosage form and clinical benefit. This target determines whether the product is a herbal preparation, purified cannabinoid, extract or conventional pharmaceutical formulation.
A target product profile that does not distinguish cannabis-specific attributes — cannabinoid ratio, terpene retention, route-specific bioavailability — from generic pharmaceutical development criteria will miss the risks that most commonly derail cannabis product programmes.
Starting material and active substance
For plant-derived products, genetics, cultivation, harvest, drying and extraction must be controlled. The developer should define what constitutes the active substance and which constituents are controlled as active, markers, impurities or degradation products.
The starting material and active substance boundary is where many cannabis development programmes lose time — treating GACP material as equivalent to a conventional API without establishing the necessary characterisation and control strategy.
Pharmaceutical development
Formulation and process development identify critical quality attributes and process parameters. Dose uniformity, solubility, absorption, packaging and device performance are considered. ICH Q8 principles help link product design to manufacturing control.
Pharmaceutical development for cannabis formulations must account for the inherent variability of a botanical starting material, which behaves differently from a synthetic active ingredient at every stage from blending to stability.
Analytical and stability programme
Methods must characterise identity, assay, impurities, contaminants and performance. Stability studies establish shelf life and storage. Cannabis products may require monitoring of acidic and neutral cannabinoids, oxidation products, moisture and volatile components.
An analytical and stability programme designed around cannabinoid assay alone will miss terpene loss, CBN formation and microbiological change — all of which affect product performance independently of potency.
Non-clinical development
Toxicology, pharmacology, interactions and local tolerance may require study depending on prior knowledge, route and exposure. A botanical product cannot assume that all constituents are harmless because the plant has historical use.
Non-clinical development for cannabis products frequently relies on published literature for the parent cannabinoids rather than new studies on the specific formulation, a gap that should be identified and justified early, not discovered at submission.
Clinical development
Clinical studies should establish dose, safety and efficacy for the proposed indication. Pharmacokinetics can be highly variable for oral cannabinoids. Device technique and product standardisation influence outcomes.
Clinical development pathways for cannabis medicines vary by product classification and target indication; the evidence bar for a novel formulation differs substantially from that for a product relying on an existing monograph.
Scale-up and process validation
The process must be transferred from development to commercial manufacture. Botanical variability, extraction yield, mixing, filling and packaging need validation and continued verification.
Scale-up introduces process variability that laboratory-scale development may not reveal, particularly around extraction yield consistency and decarboxylation uniformity across larger batch sizes.
Regulatory submission and lifecycle
The dossier integrates quality, non-clinical and clinical evidence. After authorisation, pharmacovigilance, variations, stability, complaints and product-quality review continue throughout the lifecycle.
Regulatory submission strategy should be planned from the earliest development stage — retrofitting a development programme to match submission requirements discovered late is the single most common cause of cannabis product delay.
Practical reference table
| Development stage | Core question | Cannabis-specific challenge |
|---|---|---|
| Target profile | What benefit and route are intended? | Avoid vague wellness positioning |
| Starting material | What exactly is the active substance? | Complex and variable composition |
| Formulation | Can dose be delivered consistently? | Low solubility and device dependence |
| Analytics | Can relevant constituents be measured? | Acidic/neutral forms and matrix effects |
| Clinical | Does the product work at the proposed dose? | Variable exposure and expectations |
| Commercialisation | Can manufacture remain controlled? | Agricultural and process variability |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Does historical cannabis use replace clinical trials?
No. The evidence package depends on the product and claim.
What is the active substance in a cannabis extract?
It must be defined scientifically and regulatorily; it may be the extract as a whole or specified constituents.
Why is oral cannabinoid development difficult?
Absorption and first-pass metabolism can create variable exposure.
Can a cultivar name define a medicine?
No. Pharmaceutical identity requires controlled specifications and evidence.
What continues after approval?
Pharmacovigilance, stability, change control, variations and ongoing process oversight.
Primary references and guidance
- Directive 2001/83/EC
- ICH Q8(R2)
- ICH Q9(R1)
- ICH Q10
- ICH Q1A(R2)
- ICH Q2(R2)
- ICH Q14
- EMA guidelines on herbal medicinal product quality
- EU GMP Guide
- EMA EPARs for authorised cannabinoid medicines
Confirm the current effective version and national applicability before operational, medical or regulatory use.